Abound Bio | People


Unmatched Expertise

Abound Bio was founded by renowned experts with a track-record of success and vast depth of knowledge. Supported by a team of highly skilled scientists, Dr. John Mellors and Dr. Dimiter Dimitrov bring unique and complementary skillsets highly desired by the biopharmaceutical industry.

Management Team

John Mellors, MD


Dimiter Dimitrov, PhD, ScD


Scientific Advisory Board

Joel B. Nelson, MD

SAB Chairman

Prasad S Adusumilli, MD, FACS

Ronald J. Buckanovich, MD, PHD

Rimas Orentas, PhD


Cynthia Adams, MSc

Director of Pre-Clinical Development, Scientist

Abigail Berrios

Laboratory Technician

Alex Conard, MBA, MS

Laboratory Management Director, Senior Scientist

Edward Goncz, MS


Chiquita Hanindya

Associate Scientist

Jinhong Kim, PhD


Gabriella Merritt

Director of Operations

Taylor Napierkowski

Laboratory Technician

Eric Peterson

Senior Scientist

Zehua Sun, PhD

Principal Scientist

Haiyang Zheng

Associate Scientist I

John Mellors, MD


Dr. Mellors is Chief of Infectious Diseases and Distinguished Professor at the University of Pittsburgh and UPMC. As Division Chief, he manages over 200 personnel. He has over 30 years of experience in laboratory science, clinical investigation and consultation for pharmaceutical development. He has published more than 400 publications and multiple patents. He is co-founder of Infectious Disease Connect, a telemedicine company specializing in diagnosis, treatment and prevention of infectious diseases.

Dimiter Dimitrov, PhD, ScD

Executive Vice President and Chief Scientific Officer

Dr. Dimitrov is a world-leading antibody scientist and engineer with more than 30 years of experience. He was tenured Senior Investigator in the National Cancer Institute and appointed at the Senior Biomedical Research Service at the NIH; currently he is Professor of Medicine and Director of the Center for Antibody Therapeutics at the University of Pittsburgh Medical School. He has over 400 publications, 100 patents, and multiple discoveries leading to one therapeutic antibody approval, several others in multiple clinical trials, and many more in preclinical development.

Joel B. Nelson, MD

Dr. Nelson is Frederic N. Schwentker Professor and Chairman of the Department of Urology at the University of Pittsburgh School of Medicine

Co-director of the University of Pittsburgh Cancer Institute’s Comprehensive Prostate and Urologic Cancer Center

Prasad S Adusumilli, MD, FACS

Dr. Adusumili is Professor at the Memorial Sloan-Kettering Cancer Center.

He is a leader in CAR-T cell therapy of solid tumors.

Ronald J. Buckanovich, MD, PHD

Dr. Buckanovich is Professor of Medicine, University of Pittsburgh, Director of the Ovarian Cancer Center of Excellence

Co-Director of the Women’s Cancer Research Center

Rimas J. Orentas, PhDD

Dr. Orentas is Professor of Pediatrics at the University of Washington and Principal Investigator, Ben Towne Center for Childhood Cancer Research, and also serves as Scientific Director for Caring Cross.


He is a leader in CAR-T cell biology, therapy of liquid tumors and the genetic engineering of immune effector cells.

Kurt Gehlsen

Consultant, Strategic and Business Development

Highly experienced senior executive with 30+ year’s experience in private and public companies, company formation and growth, technology and company investments, pharmaceutical and medical device product development, basic research, clinical development, regulatory affairs, strategic planning, business development, licensing, project management, investor relations and executive management.